uly 12, 2016—Sirtex Medical Ltd announced the presentation of new data that suggest that patients with liver-dominant metastatic colorectal cancer (mCRC) who underwent first-line treatment with mFOLFOX6 and SIR-Spheres yttrium-90 (Y-90)… Leer noticia completa
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.